NCT06655311View on ClinicalTrials.gov

A Study of Enlicitide Chloride (MK-0616) in Healthy Participants and Participants Taking Statins (MK-0616-012)

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

September 30, 2022

Primary Completion Date

January 2, 2024

Study Completion Date

January 2, 2024

Conditions
HealthyHypercholesterolemia
Interventions
BIOLOGICAL

Enlicitide Chloride

Oral administration

OTHER

Placebo

Oral administration

Trial Locations (1)

66212

Altasciences Clinical Kansas, Inc. (Site 0002), Overland Park

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY